Anti-HCMV compositions and methods
Inventors
Remiszewski, Stacy • Koyuncu, Emre • Sun, Qun • Chiang, Lillian
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Evrys BioEvrys Bio is a pioneering biotechnology company focused on developing broad-spectrum antiviral therapies. Founded on breakthrough discoveries from Princeton University, the company aims to transform the treatment of viral infections by targeting human proteins known as sirtuins. This innovative approach enhances the body's natural immunity, offering a high barrier to drug resistance and addressing multiple viruses simultaneously. Evrys Bio's vision is to provide first-in-class antivirals that are safe and effective against a wide range of infectious diseases, ultimately transforming medical practice by focusing on disease conditions rather than individual viruses.
Evrys Bio is a pioneering biotechnology company focused on developing broad-spectrum antiviral therapies. Founded on breakthrough discoveries from Princeton University, the company aims to transform the treatment of viral infections by targeting human proteins known as sirtuins. This innovative approach enhances the body's natural immunity, offering a high barrier to drug resistance and addressing multiple viruses simultaneously. Evrys Bio's vision is to provide first-in-class antivirals that are safe and effective against a wide range of infectious diseases, ultimately transforming medical practice by focusing on disease conditions rather than individual viruses.
Publication Number
US-11358961-B2
Publication Date
2022-06-14
Expiration Date
2035-11-09
Abstract
Novel compounds useful for treating and/or preventing HCMV infections are provided.
Core Innovation
The invention provides novel compounds described by Formula I and related formulas, wherein variables such as Ar, Y, Ring B, and various substituents are specifically defined. These compounds, and their pharmaceutically acceptable salts, are disclosed as being useful for treating and/or preventing infections caused by human cytomegalovirus (HCMV). Several structural embodiments are described, including Formulas II, III, IV, V, VI, and VII, with variations for the defined groups and substituents.
The core problem addressed is the need for improved therapeutic agents for HCMV infection. HCMV poses significant risks, particularly to immunosuppressed patients such as organ transplant recipients, with existing antiviral drugs having issues such as nephrotoxicity and increasing drug resistance. The invention aims to provide new compounds that can inhibit HCMV production, overcome drug resistance, and reduce adverse side effects associated with current treatments.
The patent also provides methods for administering a therapeutically effective amount of one or more of these compounds to prevent, treat, or ameliorate HCMV infections. Additionally, pharmaceutical compositions containing these compounds and methods for inhibiting HCMV production in infected cells are disclosed. The compounds may be administered alone or in conjunction with other antiviral agents via various routes of administration, including oral, parenteral, topical, or rectal.
Claims Coverage
The independent claim covers one inventive feature concerning the composition comprising a specific compound.
Composition comprising a compound of Formula VI or a pharmaceutically acceptable salt thereof
The inventive feature is a composition that includes a compound of Formula VI: - The compound is defined by the structural variables X1 and X2, independently selected from C and N, and all other variables as defined for Formula I. - The composition can also include pharmaceutically acceptable salts of the compound. - This coverage establishes the foundational claim for the anti-HCMV compositions based on the disclosed structural formula.
The claims primarily cover pharmaceutical compositions comprising compounds of Formula VI or their pharmaceutically acceptable salts, establishing coverage for these structurally defined anti-HCMV agents.
Stated Advantages
The compounds are effective for treating and/or preventing HCMV infections.
The compounds can inhibit HCMV production in infected cells.
Documented Applications
Treatment, prevention, or amelioration of human cytomegalovirus (HCMV) infections in subjects, including humans and other animals.
Use as antiviral agents in pharmaceutical compositions for treating or preventing HCMV infections.
Interested in licensing this patent?